Antimicrobial stewardship and IV-to-oral switch

01Purpose and principlesWhat the treatment does and how it fits into care.

Stewardship optimises the individual patient's outcome while reducing avoidable toxicity, Clostridioides difficile infection and resistance. It is not automatic restriction. The first prescription may need broad urgent cover; the quality test is whether the decision is documented, sampled appropriately and revisited when microbiology and clinical response improve certainty.

The switch decision has four domains: infection, patient, oral drug and care setting. The source must be controlled and suitable for oral treatment; the patient must be haemodynamically stable and able to absorb; the oral agent must cover the pathogen at an adequate dose; and follow-up must support adherence, monitoring and action on pending results.

Discharge can make a poor plan less visible. Reconcile total course length including inpatient doses, remove redundant duplicate therapy, communicate culture results and monitoring, and state who will review. Long courses need a clear indication, toxicity plan and stop date rather than an open-ended repeat prescription.

Key points

Every antimicrobial needs an indication, agent, dose, route, start time, review time and intended duration or stop criterion visible in the record.
Review at 48 to 72 hours using diagnosis, cultures, source control, physiology and toxicity: stop, narrow, switch, continue with an end date or revise the diagnosis.
IV-to-oral switch requires clinical improvement, stable haemodynamics, functioning gastrointestinal absorption and an oral option that achieves adequate exposure at the infected site.
Oral does not mean weak: high-bioavailability agents can produce reliable systemic exposure, while some oral beta-lactams are unsuitable for infections needing sustained high concentrations.
Some infections need specialist plans before switching, including endocarditis, meningitis, severe bone or joint infection, undrained abscess and Staphylococcus aureus bacteraemia.
Shorter evidence-based courses reduce toxicity and resistance; persistent biomarkers alone should not extend treatment when the patient and source have improved.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Ready for oral switch

Improving physiology, afebrile or clearly improving fever, functioning gut, controlled source and an effective oral option together support route review.

Unsafe switchRed flag

Shock, escalating oxygen, persistent bacteraemia, vomiting, ileus, malabsorption or a high-risk deep focus argues against routine oral conversion.

Unnecessary treatment

Alternative diagnosis, contaminant culture, colonisation or resolved self-limited illness may justify stopping rather than finding an oral substitute.

Excessive duration

A patient improving after source control may still have an inherited long end date; compare the total planned course with current syndrome guidance.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Clinical trajectory and observationsFirst step
Why
Establish whether infection and organ dysfunction are genuinely improving.
Interpretation and limitations
Stable pressure, falling oxygen need, improving mental state and oral intake carry more weight than an isolated inflammatory marker.
02
Culture and susceptibility review
Why
Confirm the pathogen and whether a narrower active oral option exists.
Interpretation and limitations
Distinguish pathogen from coloniser or contaminant. Check oral breakpoints, site penetration and resistance mechanisms with microbiology.
03
Renal and hepatic function
Why
Select oral dose and identify toxicity or altered clearance before discharge.
Interpretation and limitations
Dose may need revision again as acute kidney injury recovers; communicate timing of repeat blood tests.
04
Absorption and interaction assessment
Why
Identify vomiting, ileus, malabsorption, enteral-feed interaction and medicines that reduce or increase exposure.
Interpretation and limitations
Doxycycline and fluoroquinolones interact with polyvalent cations; rifampicin induces many drugs; QT-prolonging combinations require risk review.
05
Source-control confirmation
Why
Verify that obstruction, pus, necrotic tissue or infected hardware has been addressed.
Interpretation and limitations
Persistent anatomical infection is not corrected by changing route. Unexpected non-response requires imaging or procedural reassessment before discharge.

04Treatment approachPreparation, options, escalation and aftercare.

0148-to-72-hour reviewMake one explicit stewardship decisionFirst stepEmpirical antimicrobial therapy has continued long enough for early response and microbiology to become available.

1Reconfirm diagnosis and source, assess physiology and toxicity, review cultures, imaging, procedures and all administered doses.
2Choose stop, narrow, IV-to-oral switch, continued IV with indication, or broaden only for a new supported hypothesis; document rationale.
3Set total duration and next review, update allergy and resistance information and communicate pending results to the responsible team.

02Oral switchMatch exposure to infectionThe patient is improving and an active oral medicine may complete treatment.

1Confirm haemodynamic stability, improving fever and organ function, working gastrointestinal absorption, source control and absence of a specialist exclusion.
2Select an oral agent and dose with adequate bioavailability, susceptibility and site penetration; reconcile interactions, renal function and allergy.
3Observe initial tolerance when needed, state the inclusive stop date and arrange clinical and laboratory follow-up after discharge.

03Not improvingStop changing route and reassess causePhysiology or focal symptoms worsen, bacteraemia persists or oral intake fails.

1Return to ABCDE when unstable and verify that every intended dose was administered and absorbed.
2Investigate source-control failure, resistant infection, superinfection, thrombosis, drug fever or non-infectious mimic with targeted sampling and imaging.
3Use microbiology and specialty input to revise agent, route and duration, with a new explicit response checkpoint.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Provides narrow oral treatment for susceptible respiratory, urinary and other infections when site and organism are appropriate.

Amoxicillin oral

A common adult dose is 500 mg orally three times daily; severe indications may require higher guideline doses.

Check immediate beta-lactam allergy, renal function and indication; avoid using this example for meningitis, endocarditis or resistant organisms without specialist guidance.

Offers high oral bioavailability for selected respiratory, atypical, skin and zoonotic infections.

Doxycycline oral

Common adult treatment is 200 mg on day one then 100 mg once daily, with regimen varying by indication.

Review pregnancy, oesophageal irritation, photosensitivity, hepatic disease and cation-containing antacids or supplements; take with water while upright and use syndrome-specific duration.

Supplies oral anaerobic activity when a mixed infection genuinely requires it.

Metronidazole oral

A common adult anaerobic regimen is 400 mg orally three times daily, with duration determined by source control.

Review liver disease, neurological toxicity with prolonged use, alcohol advice and warfarin interaction; do not continue after adequate drainage without a supported indication.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

Record the formal 48-to-72-hour decision and the evidence supporting it, including why intravenous therapy remains necessary if no switch occurs.
Reconcile total duration from the first active dose and source-control date so hospital and community prescriptions do not accidentally duplicate a full course.
Check gastrointestinal tolerance, adherence, renal and hepatic recovery, interactions and new rash or diarrhoea after oral conversion.
Assign responsibility for pending cultures, susceptibility updates and outpatient blood monitoring before discharge.
Audit intravenous line days, broad-spectrum days and avoidable duplicate cover alongside clinical outcomes rather than treating switch rate as the only target.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Stop is a valid review outcome

If infection becomes unlikely, replacing intravenous treatment with oral treatment preserves an unnecessary diagnosis and exposes the patient to further harm.

Bioavailability changes the comparison

An appropriately dosed high-bioavailability oral medicine can match systemic exposure, but infection site and evidence still determine whether switch is safe.

The line has risk

Continued intravenous treatment adds thrombosis, infection, mobility and discharge harms that must be weighed against any pharmacological benefit.

Duration includes every setting

Count active treatment already received in hospital when writing discharge prescriptions, unless the guideline deliberately defines duration from source control or another event.

08Common pitfallsFrequent interpretation and management errors.

01
Switching because the cannula failed rather than because criteria are met.
02
Continuing broad dual therapy when one targeted oral agent is sufficient.
03
Using a normal CRP as the sole switch criterion or a raised CRP as the sole reason to continue.
04
Forgetting interaction and absorption checks when choosing an oral agent.
05
Issuing a fresh full course at discharge without counting inpatient treatment.